Aptamer Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the global aptamer market looks promising with opportunities in diagnostic, therapeutic development, and research & development applications. The global aptamer market is expected to grow with a CAGR of 18%-20% from 2020 to 2025. The major drivers for this market are increasing research and development activities in biotechnology and pharmaceutical companies and the low cost and high efficiency of aptamers as compared to antibodies.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global aptamer market report, please download the report brochure.
In this market, nucleic aptamer is the largest type segment of aptamer, whereas diagnostics is the largest application. Growth in various segments of the aptameter market are given below:
The study includes trends and forecast for the global aptamer market by type, technology, application, end user, and region as follows:
By Type [Value ($ Million) shipment analysis for 2014 – 2025]:
Lucintel forecasts that nucleic aptamers will remain the largest type segment over the forecast period, as it has better thermodynamic and chemical stability as compared to peptide therapeutics.
Within this market, diagnostics will remain the largest application segment over the forecast period due to increasing prevalence of chronic diseases.
North America will remain the largest region over the forecast period due to increasing investment by biotechnology and pharmaceutical indusries in research and development activities related to aptamers and increasing number of research laboratories in the region.
Features of the Global Aptamer Market
Q.1 What are some of the most promising potential, high-growth opportunities for the global aptamer market by type (nucleic acid aptamers [DNA-based aptamers, RNA-based aptamers, and XNA-based aptamers] and peptide aptamers), technology (SELEX and other technologies), application (diagnostics, therapeutic development, research and development, and other applications), end user (academic and government research institutes, biotechnology and pharmaceutical companies, contract research organizations, and other end users), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global aptamer market?
Q.5 What are the business risks and threats to the global aptamer market?
Q.6 What are the emerging trends in this aptamer market and the reasons behind them?
Q.7 What are some changing demands of customers in this aptamer market?
Q.8 What are the new developments in this aptamer market? Which companies are leading these developments?
Q.9 Who are the major players in this aptamer market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this aptamer market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global aptamer market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Type (Nucleic Acid Aptamers (DNA-Based Aptamers, RNA-Based Aptamers, and XNA-Based Aptamers) and Peptide Aptamers), Technology (SELEX and Other Technologies), Application (Diagnostics, Therapeutic Development, Research & Development, and Other Applications), and End User (Academic & Government Research Institutes, Biotechnology & Pharmaceutical Companies, Contract Research Organizations, and Other End Users)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the global aptamer market looks promising with opportunities in diagnostic, therapeutic development, and research & development applications. The global aptamer market is expected to grow with a CAGR of 18%-20% from 2020 to 2025. The major drivers for this market are increasing research and development activities in biotechnology and pharmaceutical companies and the low cost and high efficiency of aptamers as compared to antibodies.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global aptamer market report, please download the report brochure.
In this market, nucleic aptamer is the largest type segment of aptamer, whereas diagnostics is the largest application. Growth in various segments of the aptameter market are given below:
The study includes trends and forecast for the global aptamer market by type, technology, application, end user, and region as follows:
By Type [Value ($ Million) shipment analysis for 2014 – 2025]:
- Nucleic Acid Aptamers
- DNA-Based Aptamers
- RNA-Based Aptamers
- XNA-Based Aptamers
- Peptide Aptamers
- Systemic Evolution of Ligands by Exponential Enrichment (SELEX)
- Other Technologies
- Diagnostics
- Therapeutic Development
- Research and Development
- Other Applications
- Academic and Government Research Institutes
- Biotechnology and Pharmaceutical Companies
- Contract Research Organizations
- Other End Users
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- The Rest of the World
- Brazil
Lucintel forecasts that nucleic aptamers will remain the largest type segment over the forecast period, as it has better thermodynamic and chemical stability as compared to peptide therapeutics.
Within this market, diagnostics will remain the largest application segment over the forecast period due to increasing prevalence of chronic diseases.
North America will remain the largest region over the forecast period due to increasing investment by biotechnology and pharmaceutical indusries in research and development activities related to aptamers and increasing number of research laboratories in the region.
Features of the Global Aptamer Market
- Market Size Estimates: Global aptamer market size estimation in terms of value ($M) shipment.
- Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.
- Segmentation Analysis: Global aptamer market size by various segments, such as type, technology, application, and end user in terms of value.
- Regional Analysis: Global aptamer market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, technology, application, end user, and region for the global aptamer market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global aptamer market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
Q.1 What are some of the most promising potential, high-growth opportunities for the global aptamer market by type (nucleic acid aptamers [DNA-based aptamers, RNA-based aptamers, and XNA-based aptamers] and peptide aptamers), technology (SELEX and other technologies), application (diagnostics, therapeutic development, research and development, and other applications), end user (academic and government research institutes, biotechnology and pharmaceutical companies, contract research organizations, and other end users), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global aptamer market?
Q.5 What are the business risks and threats to the global aptamer market?
Q.6 What are the emerging trends in this aptamer market and the reasons behind them?
Q.7 What are some changing demands of customers in this aptamer market?
Q.8 What are the new developments in this aptamer market? Which companies are leading these developments?
Q.9 Who are the major players in this aptamer market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this aptamer market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global aptamer market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Type (Nucleic Acid Aptamers (DNA-Based Aptamers, RNA-Based Aptamers, and XNA-Based Aptamers) and Peptide Aptamers), Technology (SELEX and Other Technologies), Application (Diagnostics, Therapeutic Development, Research & Development, and Other Applications), and End User (Academic & Government Research Institutes, Biotechnology & Pharmaceutical Companies, Contract Research Organizations, and Other End Users)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Aptamer Market Trends and Forecast
3.3: Global Aptamer Market by Type
3.3.1: Nucleic Acid Aptamers
3.3.1.1: DNA-Based Aptamers
3.3.1.2: RNA-Based Aptamers
3.3.1.3: XNA-Based Aptamers
3.3.2: Peptide Aptamers
3.4: Global Aptamer Market by Technology
3.4.1: Systemic Evolution of Ligands by Exponential Enrichment (SELEX)
3.4.2: Other Technologies
3.5: Global Aptamer Market by Application
3.5.1: Diagnostics
3.5.2: Therapeutic Development
3.5.3: Research and Development
3.5.4: Other Applications
3.5: Global Aptamer Market by End User
3.5.1: Academic and Government Research Institutes
3.5.2: Biotechnology and Pharmaceutical Companies
3.5.3: Contract Research Organizations
3.5.4: Other End Users
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Aptamer Market by Region
4.2: North American Aptamer Market
4.2.1: Market by Type: Nucleic Acid Aptamers (DNA-Based Aptamers, RNA-Based Aptamers, and XNA-Based Aptamers) and Peptide Aptamers
4.2.2: Market by Technology: Systemic Evolution of Ligands by Exponential Enrichment (SELEX) and Other Technologies
4.2.3: Market by Application: Diagnostics, Therapeutic Development, Research and Development, and Other Applications
4.2.4: Market by End User: Academic and Government Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations, and Other End Users
4.2.5: The United States Aptamer Market
4.2.6: The Canadian Aptamer Market
4.2.7: The Mexican Aptamer Market
4.3: European Aptamer Market
4.3.1: Market by Type: Nucleic Acid Aptamers (DNA-Based Aptamers, RNA-Based Aptamers, and XNA-Based Aptamers) and Peptide Aptamers
4.3.2: Market by Technology: Systemic Evolution of Ligands by Exponential Enrichment (SELEX) and Other Technologies
4.3.3: Market by Application: Diagnostics, Therapeutic Development, Research and Development, and Other Applications
4.3.4: Market by End User: Academic and Government Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations, and Other End Users
4.3.5: The Aptamer Market of United Kingdom
4.3.6: The German Aptamer Market
4.3.7: The French Aptamer Market
4.4: APAC Aptamer Market
4.4.1: Market by Type: Nucleic Acid Aptamers (DNA-Based Aptamers, RNA-Based Aptamers, and XNA-Based Aptamers) and Peptide Aptamers
4.4.2: Market by Technology: Systemic Evolution of Ligands by Exponential Enrichment (SELEX) and Other Technologies
4.4.3: Market by Application: Diagnostics, Therapeutic Development, Research and Development, and Other Applications
4.4.4: Market by End User: Academic and Government Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations, and Other End Users
4.4.5: The Chinese Aptamer Market
4.4.6: The Indian Aptamer Market
4.4.7: The Japanese Aptamer Market
4.5: ROW Aptamer Market
4.5.1: Market by Type: Nucleic Acid Aptamers (DNA-Based Aptamers, RNA-Based Aptamers, and XNA-Based Aptamers) and Peptide Aptamers
4.5.2: Market by Technology: Systemic Evolution of Ligands by Exponential Enrichment (SELEX) and Other Technologies
4.5.3: Market by Application: Diagnostics, Therapeutic Development, Research and Development, and Other Applications
4.5.4: Market by End User: Academic and Government Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations, and Other End Users
4.5.5: Brazilian Aptamer Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Aptamer Market by Type
7.1.2: Growth Opportunities for the Global Aptamer Market by Technology
7.1.3: Growth Opportunities for the Global Aptamer Market by Application
7.1.4: Growth Opportunities for the Global Aptamer Market by End User
7.1.5: Growth Opportunities for the Global Aptamer Market by Region
7.2: Emerging Trends in the Global Aptamer Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Aptamer Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Aptamer Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: AM Biotechnologies, LLC
8.2: Aptagen, LLC
8.3: Aptamer Sciences, Inc.
8.4: Aptamer Solutions Ltd.
8.5: Aptus Biotech S.L.
8.6: Base Pair Biotechnologies, Inc.
8.7: NeoVentures Biotechnology
8.8: SomaLogic Inc.
8.9: TriLink BioTechnologies, Inc.
8.10: Vivonics, Inc.
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Aptamer Market Trends and Forecast
3.3: Global Aptamer Market by Type
3.3.1: Nucleic Acid Aptamers
3.3.1.1: DNA-Based Aptamers
3.3.1.2: RNA-Based Aptamers
3.3.1.3: XNA-Based Aptamers
3.3.2: Peptide Aptamers
3.4: Global Aptamer Market by Technology
3.4.1: Systemic Evolution of Ligands by Exponential Enrichment (SELEX)
3.4.2: Other Technologies
3.5: Global Aptamer Market by Application
3.5.1: Diagnostics
3.5.2: Therapeutic Development
3.5.3: Research and Development
3.5.4: Other Applications
3.5: Global Aptamer Market by End User
3.5.1: Academic and Government Research Institutes
3.5.2: Biotechnology and Pharmaceutical Companies
3.5.3: Contract Research Organizations
3.5.4: Other End Users
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Aptamer Market by Region
4.2: North American Aptamer Market
4.2.1: Market by Type: Nucleic Acid Aptamers (DNA-Based Aptamers, RNA-Based Aptamers, and XNA-Based Aptamers) and Peptide Aptamers
4.2.2: Market by Technology: Systemic Evolution of Ligands by Exponential Enrichment (SELEX) and Other Technologies
4.2.3: Market by Application: Diagnostics, Therapeutic Development, Research and Development, and Other Applications
4.2.4: Market by End User: Academic and Government Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations, and Other End Users
4.2.5: The United States Aptamer Market
4.2.6: The Canadian Aptamer Market
4.2.7: The Mexican Aptamer Market
4.3: European Aptamer Market
4.3.1: Market by Type: Nucleic Acid Aptamers (DNA-Based Aptamers, RNA-Based Aptamers, and XNA-Based Aptamers) and Peptide Aptamers
4.3.2: Market by Technology: Systemic Evolution of Ligands by Exponential Enrichment (SELEX) and Other Technologies
4.3.3: Market by Application: Diagnostics, Therapeutic Development, Research and Development, and Other Applications
4.3.4: Market by End User: Academic and Government Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations, and Other End Users
4.3.5: The Aptamer Market of United Kingdom
4.3.6: The German Aptamer Market
4.3.7: The French Aptamer Market
4.4: APAC Aptamer Market
4.4.1: Market by Type: Nucleic Acid Aptamers (DNA-Based Aptamers, RNA-Based Aptamers, and XNA-Based Aptamers) and Peptide Aptamers
4.4.2: Market by Technology: Systemic Evolution of Ligands by Exponential Enrichment (SELEX) and Other Technologies
4.4.3: Market by Application: Diagnostics, Therapeutic Development, Research and Development, and Other Applications
4.4.4: Market by End User: Academic and Government Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations, and Other End Users
4.4.5: The Chinese Aptamer Market
4.4.6: The Indian Aptamer Market
4.4.7: The Japanese Aptamer Market
4.5: ROW Aptamer Market
4.5.1: Market by Type: Nucleic Acid Aptamers (DNA-Based Aptamers, RNA-Based Aptamers, and XNA-Based Aptamers) and Peptide Aptamers
4.5.2: Market by Technology: Systemic Evolution of Ligands by Exponential Enrichment (SELEX) and Other Technologies
4.5.3: Market by Application: Diagnostics, Therapeutic Development, Research and Development, and Other Applications
4.5.4: Market by End User: Academic and Government Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations, and Other End Users
4.5.5: Brazilian Aptamer Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Aptamer Market by Type
7.1.2: Growth Opportunities for the Global Aptamer Market by Technology
7.1.3: Growth Opportunities for the Global Aptamer Market by Application
7.1.4: Growth Opportunities for the Global Aptamer Market by End User
7.1.5: Growth Opportunities for the Global Aptamer Market by Region
7.2: Emerging Trends in the Global Aptamer Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Aptamer Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Aptamer Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: AM Biotechnologies, LLC
8.2: Aptagen, LLC
8.3: Aptamer Sciences, Inc.
8.4: Aptamer Solutions Ltd.
8.5: Aptus Biotech S.L.
8.6: Base Pair Biotechnologies, Inc.
8.7: NeoVentures Biotechnology
8.8: SomaLogic Inc.
8.9: TriLink BioTechnologies, Inc.
8.10: Vivonics, Inc.
